AMRX
Price
$6.05
Change
+$0.64 (+11.83%)
Updated
Apr 24, 6:59 PM EST
8 days until earnings call
EBS
Price
$2.17
Change
-$0.12 (-5.24%)
Updated
Apr 24, 6:59 PM EST
Earnings call today
Ad is loading...

Compare trend and price AMRX vs EBS

Header iconAMRX vs EBS Comparison
Open Charts AMRX vs EBSBanner chart's image
Amneal Pharmaceuticals
Price$6.05
Change+$0.64 (+11.83%)
Volume$1.81M
CapitalizationN/A
Emergent Biosolutions
Price$2.17
Change-$0.12 (-5.24%)
Volume$301.75K
CapitalizationN/A
View a ticker or compare two or three
AMRX vs EBS Comparison Chart

Loading...

AMRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
EBSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AMRX vs. EBS commentary
Apr 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Hold and EBS is a Hold.

COMPARISON
Comparison
Apr 25, 2024
Stock price -- (AMRX: $5.40 vs. EBS: $2.29)
Brand notoriety: AMRX and EBS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AMRX: 86% vs. EBS: 23%
Market capitalization -- AMRX: $1.87B vs. EBS: $120.07M
AMRX [@Pharmaceuticals: Other] is valued at $1.87B. EBS’s [@Pharmaceuticals: Other] market capitalization is $120.07M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileEBS’s FA Score has 1 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • EBS’s FA Score: 1 green, 4 red.
According to our system of comparison, AMRX is a better buy in the long-term than EBS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 2 TA indicator(s) are bullish while EBS’s TA Score has 5 bullish TA indicator(s).

  • AMRX’s TA Score: 2 bullish, 6 bearish.
  • EBS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, EBS is a better buy in the short-term than AMRX.

Price Growth

AMRX (@Pharmaceuticals: Other) experienced а -0.92% price change this week, while EBS (@Pharmaceuticals: Other) price change was +17.44% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.33%. For the same industry, the average monthly price growth was +27.90%, and the average quarterly price growth was +18903.16%.

Reported Earning Dates

AMRX is expected to report earnings on Aug 05, 2024.

EBS is expected to report earnings on Jul 25, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (-1.33% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for AMRX with price predictions.
OPEN
A.I.dvisor published
a Summary for EBS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AMRX($1.87B) has a higher market cap than EBS($120M). AMRX has higher P/E ratio than EBS: AMRX (90.00) vs EBS (17.73). AMRX YTD gains are higher at: -0.329 vs. EBS (-4.583). AMRX has higher annual earnings (EBITDA): 400M vs. EBS (-518.2M). EBS has more cash in the bank: 112M vs. AMRX (91.5M). EBS has less debt than AMRX: EBS (860M) vs AMRX (2.75B). AMRX has higher revenues than EBS: AMRX (2.39B) vs EBS (1.02B).
AMRXEBSAMRX / EBS
Capitalization1.87B120M1,558%
EBITDA400M-518.2M-77%
Gain YTD-0.329-4.5837%
P/E Ratio90.0017.73508%
Revenue2.39B1.02B234%
Total Cash91.5M112M82%
Total Debt2.75B860M320%
FUNDAMENTALS RATINGS
AMRX vs EBS: Fundamental Ratings
AMRX
EBS
OUTLOOK RATING
1..100
6260
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
3663
P/E GROWTH RATING
1..100
3315
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (65) in the Biotechnology industry is somewhat better than the same rating for AMRX (98) in the Pharmaceuticals Major industry. This means that EBS’s stock grew somewhat faster than AMRX’s over the last 12 months.

EBS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AMRX (100) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as EBS (98) in the Biotechnology industry. This means that AMRX’s stock grew similarly to EBS’s over the last 12 months.

AMRX's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as EBS (63) in the Biotechnology industry. This means that AMRX’s stock grew similarly to EBS’s over the last 12 months.

EBS's P/E Growth Rating (15) in the Biotechnology industry is in the same range as AMRX (33) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to AMRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXEBS
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 3 days ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 3 days ago
74%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 14 days ago
80%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
AMRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
EBSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTZCX43.810.15
+0.34%
FullerThaler Behvrll Uncnstd Eq C
FRDTX89.760.09
+0.10%
Franklin Rising Dividends C
FTWRX16.380.01
+0.06%
Templeton World R6
MSERX9.11-0.03
-0.33%
MassMutual Small Cap Growth Eq R4
JASOX23.96-0.10
-0.42%
JHancock New Opportunities A

AMRX and

Correlation & Price change

A.I.dvisor tells us that AMRX and EGRX have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMRX and EGRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
+12.04%
EGRX - AMRX
27%
Poorly correlated
-4.61%
SUPN - AMRX
25%
Poorly correlated
+1.04%
ORGO - AMRX
25%
Poorly correlated
N/A
VTRS - AMRX
25%
Poorly correlated
+1.67%
IRWD - AMRX
24%
Poorly correlated
-2.53%
More

EBS and

Correlation & Price change

A.I.dvisor tells us that EBS and INDV have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EBS and INDV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+6.02%
INDV - EBS
30%
Poorly correlated
+0.49%
ZOM - EBS
29%
Poorly correlated
+0.92%
PAHC - EBS
28%
Poorly correlated
+4.29%
SNDL - EBS
27%
Poorly correlated
+10.11%
ACET - EBS
27%
Poorly correlated
+5.00%
More